Antibodies to human IL-1β

US7491392B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Hermann Gram · Weil am Rhein, DE
• Franco E. Di Padova · Birsfelden, CH

Key dates

• Filing date: Jul 11, 2006
• Grant date: Feb 17, 2009
• Expiry date: Dec 1, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/565
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteroporosis and other inflammatory arthritides.